Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 14/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.77 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.77 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.77 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.77 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.77 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060755 | 0.94 | ADORA1 (0.89) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL14903094 | 0.93 | ADORA1 (0.86) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL7759755 | 0.89 | ADORA1 (0.80) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL7958489 | 0.89 | ADORA1 (0.80) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| Rolofylline SCHEMBL720438 | 0.87 | ADORA1 (1.00) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL7760149 | 0.86 | ADORA1 (0.75) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL7473253 | 0.86 | ADORA1 (0.76) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL1567053 | 0.86 | ADORA1 (0.74) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL1566331 | 0.85 | ADORA1 (0.73) | ADORA1ADORA2AADORA2BADORA3SLC6A3 | |
| SCHEMBL1566743 | 0.85 | ADORA1 (0.73) | ADORA1ADORA2AADORA2BADORA3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274348-A1 | ORALLY DISINTEGRATING TABLET | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-10-17 | — | — | US | disclosed |
| US-20130109645-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | The united States of America,as represented by Secretary,Dept.,of Health and Human Services (US) | 2013-05-02 | — | — | US | disclosed |
| US-20070293463-A1 | METHOD FOR SHORTENING HOSPITAL STAY IN PATIENTS WITH CONGESTIVE HEART FAILURE AND ACUTE FLUID OVERLOAD | NOVACARDIA, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293463-A1 | METHOD FOR SHORTENING HOSPITAL STAY IN PATIENTS WITH CONGESTIVE HEART FAILURE AND ACUTE FLUID OVERLOAD | NOVACARDIA, INC. | 2007-12-20 | — | — | US | disclosed |
| EP-0415456-B1 | Xanthine compounds | KYOWA HAKKO KOGYO KK (JP) | 1996-06-26 | — | — | EP | disclosed |
| US-5525607-A | DIURETICS, BRONCHODILATORS, RENAL PROTECTING AGENTS | KYOWA HAKKO KOGYO CO., LTD (JP) | 1996-06-11 | — | — | US | disclosed |
| US-5290782-A | Bronchodilator agents, diuretics for renal protective agents | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-03-01 | — | — | US | disclosed |
| EP-0501379-A2 | Xanthine compounds | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-09-02 | — | — | EP | disclosed |
| EP-0415456-A2 | Xanthine compounds | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109645-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | NT5E, NT5C2, NT5C3B | ADORA1 9/4885ADORA2A 4/4885ADORA2B 10/4885 |
| US-20130274348-A1 | ORALLY DISINTEGRATING TABLET | SI, TREH, DDOST | ADORA1 2613/4885ADORA2A 4145/4885ADORA2B 3915/4885 |
| US-20070293463-A1 | METHOD FOR SHORTENING HOSPITAL STAY IN PATIENTS WITH CONGESTIVE HEART FAILURE AND ACUTE FLUID OVERLOAD | AVPR2, NPPA, SLC5A2 | ADORA1 1487/4885ADORA2A 708/4885ADORA2B 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.